Insider · CIK 0001898644

Cohen Joshua B

Reports to the SEC for 2 companies · PALO ALTO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001898644

Forms 4 and 5

Insider transactions

47 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-10	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−29.5K sh	$32.16	−$950K	3,614,042
2026-09-10	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−919 sh	$33.15	−$30.5K	3,613,123
2026-08-18	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+60K sh	—	—	3,643,587
2026-03-05	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+249K sh	—	—	3,583,548
2026-03-05	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, Co-Chief Executive Officer	AAward	+373K sh	—	—	373,295
2026-03-02	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−29.3K sh	$14.48	−$424K	3,334,683
2026-02-02	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−15.5K sh	$14.68	−$228K	3,363,965
2026-01-16	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+2,818 sh	$7.57	+$21.3K	3,381,439
2026-01-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−1,974 sh	$13.83	−$27.3K	3,379,465
2026-01-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−2,818 sh	—	—	0
2026-01-15	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+197K sh	$7.57	+$1.49M	3,514,814
2026-01-15	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−136K sh	$13.59	−$1.85M	3,378,621
2026-01-15	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−197K sh	—	—	2,818
2026-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−7,715 sh	$11.09	−$85.6K	3,317,632
2025-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−29.7K sh	$14.34	−$426K	3,325,547
2025-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−200 sh	$15.00	−$2,999.5	3,325,347
2025-03-31	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−21.5K sh	$3.47	−$74.5K	3,355,280
2025-03-06	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+180K sh	—	—	3,376,770
2025-03-06	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, Co-Chief Executive Officer	AAward	+270K sh	—	—	270,177
2025-03-03	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−4,595 sh	$3.17	−$14.5K	3,196,652
2025-02-03	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−11.9K sh	$3.47	−$41.1K	3,201,247
2025-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−7,471 sh	$4.05	−$30.2K	3,213,098
2024-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−18.6K sh	$3.20	−$59.4K	3,220,569
2024-09-23	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+1,857 sh	$1.57	+$2,915.49	3,239,158
2024-09-23	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−1,857 sh	—	—	0
2024-09-12	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+34.4K sh	$1.57	+$54.1K	3,237,301
2024-09-12	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−34.4K sh	—	—	1,857
2024-04-16	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+180K sh	—	—	3,202,852
2024-04-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+380K sh	—	—	380,000
2024-03-05	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−4,135 sh	$18.73	−$77.4K	3,023,002
2024-02-26	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+127K sh	—	—	3,027,137
2024-02-26	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+190K sh	—	—	190,000
2024-01-09	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−5,841 sh	$16.33	−$95.4K	2,900,470
2023-11-16	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+63.7K sh	$1.57	+$100K	2,906,311
2023-11-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−63.7K sh	—	—	36,306
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−96.1K sh	$31.84	−$3.06M	2,796,541
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−3,924 sh	$32.45	−$127K	2,792,617
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+50K sh	—	—	2,842,617
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+225K sh	—	—	225,000
2023-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	+4,122 sh	$36.08	+$149K	2,894,463
2023-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	+1,846 sh	$36.79	+$67.9K	2,892,617
2022-05-05	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+335K sh	$0.37	+$124K	2,898,585
2022-05-05	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−335K sh	—	—	0
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc.C Conversion	Director, Co-Chief Executive Officer	CConversion	+4,870 sh	—	—	2,489,065
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+75K sh	—	—	2,564,065
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc. · Series C-1 Preferred StockC Conversion	Director, Co-Chief Executive Officer	CConversion	−4,870 sh	—	—	0
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+338K sh	—	—	337,500

Recent filings

Accepted (ET)
Sep 144
Cohen Joshua B0001193125-26-390507
SEC(opens sec.gov)
Aug 204
Cohen Joshua B0001193125-26-359675
SEC(opens sec.gov)
Mar 94
Cohen Joshua B0001193125-26-098440
SEC(opens sec.gov)
Mar 44
Cohen Joshua B0001193125-26-091442
SEC(opens sec.gov)
Feb 44
Cohen Joshua B0001193125-26-037552
SEC(opens sec.gov)
Jan 204
Cohen Joshua B0001193125-26-017057
SEC(opens sec.gov)
Jan 84
Cohen Joshua B0001193125-26-007666
SEC(opens sec.gov)
Oct 24
Cohen Joshua B0001193125-25-228340
SEC(opens sec.gov)
Apr 24
Cohen Joshua B0000950170-25-049513
SEC(opens sec.gov)
Mar 104
Cohen Joshua B0000950170-25-036708
SEC(opens sec.gov)
Mar 54
Cohen Joshua B0000950170-25-033719
SEC(opens sec.gov)

Companies

Address

C/O TCGX ACQUISITION CORP. II 245 LYTTON AVE., SUITE 350

PALO ALTO, CA, 94301